Close Menu

NEW YORK – Roughly three years after its launch, the Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) Network has moved beyond its initial focus on lung cancer to add analyses of multiple cancer types including a prospective, multisite study.

The network is also working to incorporate additional proteomic technologies including data-independent acquisition (DIA) mass spectrometry and imaging and top-down mass spec, said Thomas Conrads, director of women's health research at Inova Fairfax Hospital and a researcher on the APOLLO initiative.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.